The Heart Failure Society of America (HFSA) has published a new scientific statement focused on the treatment of COVID-19 patients with heart failure.
The statement, simultaneously published in the Journal of Cardiac Failure, examines current data related to COVID-19’s impact on the heart. The authors also took time to address disparities of care that have been observed since the pandemic began and certain challenges healthcare providers encounter on a daily basis.
COVID-19 vaccinations are also discussed at length, with the authors emphasizing their importance for any adults living with heart failure.
“The COVID-19 pandemic has impacted all aspects of healthcare, including how we care for our patients with heart failure,” HFSA President Nancy Albert, RN, PhD, said in a statement. “In addition to strains on hospital beds, diagnostic testing and ambulatory services, COVID-19 surges have impacted research and development of novel therapeutics, devices, medical interventions and strategies, all of which may have long-standing implications for our patients. The rise of the Delta variant of COVID-19 is a reminder that this pandemic is not over, and that the trajectory is unpredictable, as new variants may create concern nationally and internationally. The many factors and implications that surround COVID-19 speak to the importance of this position statement by the HFSA—for our patients, healthcare professionals and researchers.”
The HFSA Scientific Statements Committee developed this statement. Its lead author was Ankeet S. Bhatt, MD, MBA, of Brigham and Women's Hospital and Harvard Medical School.
Read the full scientific statement here.
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.